Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACLY drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ACLY Recombinant Protein (Full-length or Catalytic Domain) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. |
View ACLY Products |
| Mutant Panel | ACLY Mechanistic Mutants (Catalytic-dead controls D1200A/R471Q) for selectivity testing and resistance profiling. | View ACLY Products |
| Gene Delivery | ACLY Lentivirus Premade Particles (Promise-ORF) for stable cell line construction in HepG2 or HEK293. | View ACLY Products |
| Benchmark Ab | Anti-ACLY Control Antibody (Recombinant, Research Grade) for ELISA, Western Blot, and SPR assay normalization. | View ACLY Products |
| Validator | ACLY siRNA Set (3 unique sequences) for knockdown verification, target engagement, and specificity checks. | View ACLY Products |
| Related Target: FASN | Fatty Acid Synthase; Synergistic downstream target in de novo lipogenesis pathway. | View FASN Products |
| Related Target: ACACA | ACC1; Downstream rate-limiting enzyme; combines with ACLY for dual lipogenesis blockade. | View ACACA Products |
| Related Target: HMGCR | Parallel cholesterol biosynthesis pathway; combination therapy screening. | View HMGCR Products |
| Related Target: ACSS2 | Compensatory acetyl-CoA synthetase; synthetic lethality partner under ACLY inhibition. | View ACSS2 Products |
| Related Target: SREBF1 | Transcriptional regulator of ACLY; pathway feedback studies. | View SREBF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog selectivity (ACLY vs. ACACA / ACSS2) | Human ACLY, ACACA, and ACSS2 ortholog proteins available; >95% purity; Sequence Verified for off-target binding studies. |
| Cross-species preclinical translation | Species-matched recombinant ACLY proteins (Human, Mouse, Cynomolgus) with Endotoxin <1 EU/µg. |
| Enzyme purity for high-throughput screening | HEK293 Expressed, >95% purity by SDS-PAGE, Sequence Verified by Mass Spec. |
| Allosteric vs. orthosteric inhibitor discrimination | Domain-truncated variants (N-terminal vs. C-terminal) available; catalytic-dead mutants for mechanism studies. |
| Compensatory pathway (ACSS2) activation | ACLY + ACSS2 double-mutant protein panel for synthetic lethality screening. |
| Intracellular target structural stability for PROTACs | High purity (>95%), sequence verified recombinant proteins expressed with strict quality control. |
| Targeting drug resistance mutations | Custom mutant recombinant proteins (e.g., ATP-grasp domain mutants) available for rigorous selectivity profiling. |
| Lack of cellular overexpression controls | ACLY Lentivirus Premade Particles for stable HepG2 or HEK293 metabolic cell lines. |
| False positives / target engagement verification | ACLY siRNA Set included for knockdown specificity confirmation in lipogenesis rescue assays. |
Live ACLY R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACLY (ATP citrate lyase) therapeutics is intensifying, with major players shifting focus from traditional lipid-lowering agents to novel oncology and NASH interventions. As first-generation therapies like bempedoic acid (Nexletol) validate the target clinically for hypercholesterolemia, the next wave of R&D is targeting direct allosteric inhibition, liver-targeted prodrugs, targeted protein degradation (PROTACs), and siRNA-based gene silencing to overcome metabolic dependencies in solid tumors and metabolic diseases. Differentiation now focuses on tissue-specific delivery, combination regimens with SREBP1, mTOR, or immune checkpoint inhibitors, and addressing resistance mechanisms such as compensatory ACSS2 activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (incl. Prodrugs) | Esperion Therapeutics, Daiichi Sankyo, Nimbus Therapeutics, Pfizer | Dyslipidemia, ASCVD, NASH, Solid Tumors | Enzymatic Inhibition & Selectivity Panel (Need high-purity WT/Mutant & ortholog proteins) |
| PROTAC / Degrader | Early Preclinical Biotech | Solid Tumors | Ternary Complex Validation (Need strictly Sequence Verified proteins) |
| siRNA / RNAi / Gene Silencing | Alnylam, Dicerna, RNAi Platform Developers | NASH, Hyperlipidemia, Solid Tumors | Target Engagement Validation (Need validated siRNA & Lentivirus cell lines) |
| Immuno-Oncology Combo | Oncology-Focused Biotechs, Academic Consortia | Melanoma, Lung, Liver Cancers | Cell-Based Lipogenesis Assay (Need stable ORF cell lines) |
| Combination Therapy (Metabolic) | Academic Consortia | Metabolic Syndrome, NASH | Pathway Panel Screening (Need ACSS2/ACACA/FASN proteins) |